Document is current
Any future updates will be listed below
-
Authors
Le Saux, Olivia http://orcid.org/0000-0002-7815-323X
Ardin, Maude
Berthet, Justine
Barrin, Sarah
Bourhis, Morgane http://orcid.org/0000-0002-3237-9858
Cinier, Justine
Lounici, Yasmine
Treilleux, Isabelle
Just, Pierre-Alexandre
Bataillon, Guillaume
Savoye, Aude-Marie
Mouret-Reynier, Marie-Ange http://orcid.org/0000-0001-6981-1678
Coquan, Elodie
Derbel, Olfa
Jeay, Louis http://orcid.org/0009-0008-4161-040X
Bouizaguen, Suliman
Labidi-Galy, Intidhar http://orcid.org/0000-0002-0824-3475
Tabone-Eglinger, Séverine http://orcid.org/0000-0003-4247-1321
Ferrari, Anthony
Thomas, Emilie
Ménétrier-Caux, Christine http://orcid.org/0000-0003-4863-374X
Tartour, Eric http://orcid.org/0000-0002-7323-468X
Galy-Fauroux, Isabelle http://orcid.org/0000-0001-8477-051X
Stern, Marc-Henri http://orcid.org/0000-0002-8100-2272
Terme, Magali
Caux, Christophe
Dubois, Bertrand
Ray-Coquard, Isabelle http://orcid.org/0000-0003-2472-8306
-
Funding
Funding for this research was provided by:
Fondation ARC pour la Recherche sur le Cancer (PGA1 RC20170205307)
- License Information
-
More Information
Article History
Received: 25 February 2023
Accepted: 18 March 2024
First Online: 16 July 2024
Competing interests
: O.L.S. reports honoraria from MSD and Clovis, and travel/accommodation/expenses from Eisai. E.C. reports the following, all for an immediate family member: employment with Sanofi; consulting/advisory role for MSD, BMS, Ipsen, and AstraZeneca; speakers’ bureau for BMS, Ipsen, AstraZeneca, and Janssen; research funding from Pfizer; and travel/accommodation/expenses from Janssen. I.R-C reports personal honoraria from Agenus, Blueprint, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, MacroGenics, Tesaro, and Clovis; honoraria to her institution from GSK, MSD, Roche, and BMS; consulting/advisory roles for AbbVie, Agenus, Advaxis, BMS, PharmaMar, Genmab, Pfizer, AstraZeneca, Roche/Genentech, GSK, MSD, Deciphera, Mersana, Merck Sereno, Novartis, Amgen, Tesaro and Clovis; research grant/funding from MSD, Roche and BMS (self) and MSD, Roche, BMS, Novartis, AstraZeneca and Merck Sereno (to institution); and travel support from Roche, AstraZeneca, and GSK. Other authors declare no competing interests.
